IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.
创建时间：
2023-03-15
